A landmark initiative in 2026 is the Generation Study, led by Genomics England in partnership with the NHS.

This pilot program involves the WGS of 100,000 newborns. The goal is to identify over 200 rare but treatable genetic conditions that may not be detected by the traditional "heel prick" test. By 2026, early data suggests that this proactive screening allows for immediate life-saving interventions (such as specialized diets or enzyme replacement therapies) before permanent organ damage or developmental delays occur.